Browse the evidence

Exogenous testosterone therapy increases the risk of cardiovascular-related events in men, with an overall odds ratio of 1.54 compared to placebo.

If you are considering testosterone therapy, be aware that it may increase your risk of cardiovascular events. The overall risk is about 1.5 times higher than placebo. This risk appears higher in trials not funded by pharmaceutical companies. Discuss this risk with your doctor, especially if you have existing heart conditions or are older.

The increased risk of cardiovascular events associated with testosterone therapy is significantly higher in trials not funded by the pharmaceutical industry compared to those that are.

Be cautious about the source of information regarding testosterone safety. Independent studies suggest a higher risk of heart-related events than industry-sponsored studies. If you are taking testosterone, ensure your doctor is monitoring your cardiovascular health closely, especially if you have other risk factors.

Synthetic exendin-4 (exenatide) significantly reduces both fasting and postprandial plasma glucose in patients with type 2 diabetes through glucose-dependent insulin secretion, glucagon suppression, and slowed gastric emptying.

For patients with Type 2 Diabetes, synthetic exendin-4 (exenatide) is an effective treatment that lowers blood sugar both after meals and while fasting. It works by boosting insulin only when blood sugar is high, suppressing excess glucagon, and slowing down how fast food leaves the stomach. While it requires twice-daily injections and may cause temporary nausea, it offers a distinct advantage over some older medications by not causing hypoglycemia and potentially preserving beta-cell function.

Chronic circadian disruption, modeled by housing mice in incongruous 20-hour light/dark cycles, causes accelerated weight gain, obesity, and metabolic dysregulation (elevated insulin and leptin) despite unchanged food consumption.

If you work shifts or have irregular sleep/wake cycles, your body may gain weight and develop insulin resistance even if you don't change your diet. This is because your internal biological clock is desynchronized from your environment. Prioritizing consistent sleep-wake times and light exposure may help mitigate these metabolic risks.

Chronic circadian disruption reduces cognitive flexibility and alters emotionality by causing structural remodeling (loss of dendritic complexity) in the prelimbic prefrontal cortex.

Irregular sleep schedules can physically alter your prefrontal cortex, reducing your ability to adapt to new information and increasing emotional reactivity. Maintaining a consistent sleep-wake cycle, even on days off, protects your brain structure and cognitive flexibility.

Artificial intelligence techniques, including fuzzy logic, neural networks, and reinforcement learning, are effective tools for automating blood glucose control and prediction in diabetes management, improving glycemic outcomes and reducing hypoglycemia risk compared to traditional methods or manual management.

For patients using insulin pumps or continuous glucose monitors (CGM), AI-driven 'artificial pancreas' systems can automatically adjust insulin delivery based on real-time glucose readings. This technology has been shown in multiple studies to improve blood sugar control and reduce dangerous low-blood-sugar events, particularly at night, compared to standard pump therapy. Patients should consult their endocrinologist about AI-integrated devices if they struggle with manual dose calculations or frequent hypoglycemia.

Premenopausal women are protected from developing NAFLD due to estrogen-mediated partitioning of fatty acids toward ketone body production and sex-specific browning of white adipose tissue, whereas postmenopausal estrogen deficiency facilitates massive hepatic steatosis and fibrotic progression.

For women, reproductive status is a critical factor in liver health. Before menopause, estrogen helps protect the liver by directing fat away from storage in the liver and towards energy use (ketones). After menopause, this protection vanishes, significantly increasing the risk of fatty liver and scarring, even if weight doesn't change drastically. Maintaining metabolic health becomes even more crucial post-menopause to counteract this hormonal shift.

Postmenopausal women have a higher prevalence of NAFLD than premenopausal women, and this risk is independently associated with menopause status even after adjusting for metabolic factors in some studies.

After menopause, your risk of fatty liver disease increases significantly, even if you maintain a healthy weight. This is largely due to the loss of estrogen. Regular liver health monitoring is recommended for postmenopausal women.

Bariatric surgery (specifically metabolic procedures like Roux-en-Y gastric bypass) produces greater diabetes remission and weight loss than purely restrictive procedures (like gastric banding) due to hormonal and neural changes.

If you have extreme obesity, metabolic surgery (like gastric bypass) is more effective than restrictive surgery (like bands) for curing diabetes and losing weight because it changes your gut hormones, not just your stomach size. Discuss with a specialist if you are a candidate.

Reduction of dietary intake (Dietary Restriction) extends lifespan by modulating the proteostasis machinery, specifically by reducing translation rates and enhancing autophagy, thereby preventing the accumulation of misfolded proteins.

Dietary restriction, specifically reducing caloric intake to approximately 60% of ad libitum levels, has been shown to extend lifespan in multiple species by modulating proteostasis. This involves reducing protein translation and enhancing autophagy to clear misfolded proteins. While the exact human application requires further research, the mechanism suggests that controlled caloric reduction may support cellular health and longevity.

Reduced Insulin/IGF-1 Signaling (IIS) extends lifespan by allowing transcription factors like DAF-16 and HSF-1 to enter the nucleus and activate proteostasis genes, including chaperones and autophagy components.

Reduced Insulin/IGF-1 Signaling (IIS) extends lifespan by allowing transcription factors like DAF-16 and HSF-1 to enter the nucleus and activate proteostasis genes, including chaperones and autophagy components.

Autophagy induction, particularly macroautophagy, is necessary for lifespan extension by Dietary Restriction and reduced IIS, and pharmacological induction (e.g., rapamycin) can increase longevity.

Inducing autophagy, either through Dietary Restriction or pharmacological agents like rapamycin, extends lifespan. Rapamycin treatment in mice at 600 days significantly increased longevity, suggesting that enhancing cellular cleanup mechanisms is a viable strategy for promoting healthspan.

Circulating miR-19a/b and miR-125b are associated with features of metabolic syndrome and cardiovascular disease risk, including biomarkers of atherosclerosis.

Elevated levels of miR-19a/b and miR-125b in the blood may signal an increased risk of cardiovascular issues and metabolic dysfunction in people with fatty liver. This suggests that liver health is closely tied to heart health, and monitoring these markers could help assess overall metabolic risk.

Liver expression of miR-122 is downregulated in NASH compared to simple steatosis, despite being upregulated in the serum, suggesting a release mechanism from lipid-laden hepatocytes.

In advanced fatty liver disease (NASH), the liver itself contains less miR-122, but more of it is found in the blood. This suggests that as liver damage progresses, the liver releases this molecule into the bloodstream, making blood tests a useful proxy for liver health.

Activation of the GLP-1 receptor promotes pancreatic beta-cell proliferation and inhibits apoptosis, leading to expanded beta-cell mass and improved glucose tolerance in diabetic animal models.

GLP-1 based therapies (like exendin-4 or liraglutide) do more than just lower blood sugar; they appear to help the pancreas grow more insulin-producing cells and protect existing ones from dying in diabetic animal models. This suggests a potential disease-modifying benefit beyond glucose control.

Ethanol consumption activates Sterol Regulatory Element-binding Protein-1 (SREBP-1) via its metabolite acetaldehyde, leading to increased transcription of lipogenic genes (FAS, SCD, ACL, ME) and subsequent hepatic triglyceride accumulation (fatty liver).

Alcohol consumption directly promotes fat storage in the liver by activating specific genes (SREBP-1) that build fat, independent of just the calories consumed. This happens because your body converts alcohol into acetaldehyde, which triggers this fat-building pathway. To minimize fatty liver risk, limiting alcohol intake is critical, as even moderate amounts can drive this process.

HOMA-IR cut-off values for identifying metabolic syndrome should be lowered and adjusted for age and gender rather than using fixed population percentiles, as lower thresholds (e.g., 1.85-2.05) better identify cardio-metabolic risk.

If you are being screened for insulin resistance using HOMA-IR, do not assume a single 'normal' number applies to you. Your risk profile changes with age and gender. For non-diabetic women, the threshold for concern drops as they age past 50. Ask your provider to interpret your HOMA-IR score in the context of your specific metabolic risk factors (blood pressure, lipids, waist size) rather than a generic population average.

Human adipose tissue contains persistent brown adipocytes expressing beta-3 adrenergic receptors (beta-3-AR) and uncoupling protein (UCP) mRNA throughout life, particularly in deep deposits like perirenal and omental fat, enabling thermogenesis and lipid metabolism regulation.

Your deep abdominal fat (around your organs) is not just inert storage; it contains active brown fat cells that can burn energy. These cells are regulated by beta-3 receptors. While this paper doesn't prescribe a drug, it suggests that targeting these specific receptors could theoretically help manage body fat and lipid metabolism by activating this hidden thermogenic capacity.

Stimulating de novo adipogenesis (adipocyte hyperplasia) in visceral white adipose tissue during caloric excess drives healthy tissue remodeling, maintaining insulin sensitivity and preventing metabolic syndrome.

Focus on where your body stores fat and how it handles it, not just the scale. Visceral fat accumulation and inability to create new fat cells (hyperplasia) are key drivers of metabolic disease. While you cannot directly 'choose' where fat goes, maintaining metabolic health through exercise and diet supports healthy adipose function. Avoid extreme caloric deficits that may overwhelm adipose expandability, leading to ectopic fat storage in organs.

Fibro-inflammatory progenitors (FIPs) in adipose tissue are anti-adipogenic and promote inflammation and fibrosis, contributing to unhealthy adipose remodeling.

Chronic inflammation in fat tissue can be driven by specific cell types (FIPs) that block healthy fat storage. Managing inflammation through diet and exercise may help reduce the activity of these anti-adipogenic cells, allowing for healthier fat tissue expansion.

Administration of the intestine-restricted FXR agonist fexaramine (FEX) improves glucose tolerance and promotes adipose tissue browning in mice by reshaping gut microbiota to increase lithocholic acid (LCA) production, which activates TGR5/GLP-1 signaling.

This research suggests that specific bile acid signaling, influenced by gut bacteria, plays a key role in how your body handles sugar and fat storage. While this study used a specific drug (fexaramine) in mice, it highlights the importance of gut health in metabolic regulation. For now, there is no direct human supplement equivalent, but maintaining a diverse gut microbiome through diet is a logical step to support these natural pathways.

Acute total sleep deprivation (24 hours) significantly increases plasma levels of serotonin, tryptophan, and taurine compared to normal sleep, potentially explaining the antidepressant effects of sleep loss.

One night of staying awake all night significantly raises levels of serotonin, tryptophan, and taurine in your blood. This chemical shift is linked to why sleep deprivation can sometimes temporarily lift mood (antidepressant effect), but it also disrupts normal metabolic rhythms. Prioritizing regular sleep helps maintain stable neurotransmitter levels and metabolic health.

Human immune function exhibits significant seasonal variation, with a pro-inflammatory transcriptomic profile and increased circulating levels of risk biomarkers (sIL-6R, CRP) during winter months in temperate climates.

If you live in a temperate climate, your immune system is biologically wired to be more inflammatory in winter. This is an evolutionary adaptation, not just a reaction to germs. Be aware that this internal shift may increase your baseline risk for inflammatory conditions during winter months, regardless of your lifestyle choices.

The cellular composition of peripheral blood changes seasonally, with white blood cell counts and specific lineages (lymphocytes, monocytes, neutrophils) varying significantly by season in temperate regions.

Your blood cell counts are not static; they fluctuate with the seasons. This is a normal physiological variation, not necessarily a sign of disease, but it contributes to the overall seasonal immune profile.